A Modular Open Label, Signal Seeking, Phase II Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations (TARGET-VM)
Latest Information Update: 29 Nov 2024
Price :
$35 *
At a glance
- Drugs Alpelisib (Primary) ; Mirdametinib (Primary)
- Indications Vascular malformations
- Focus Therapeutic Use
- Acronyms TARGET-VM
- 24 Nov 2024 Status changed from not yet recruiting to recruiting.
- 27 Sep 2024 Planned initiation date changed from 1 Aug 2024 to 1 Oct 2024.
- 13 Jun 2024 Planned End Date changed from 1 Nov 2026 to 1 Dec 2026.